Envista (NVST) Q4 2024 earnings summary

Executive summary

• Q4 2024 results met expectations with 2% core growth and a 13.9% adjusted EBITDA margin, supported by operational improvements and leadership changes.

• Spark aligners and implants showed growth and share gains, while the dental market remained soft but stable, with headwinds in China and diagnostics.

• FY24 free cash flow reached $303 million, up 35% year-over-year, supporting a $250 million share repurchase authorization.

• Full-year 2024 net loss was $1.12 billion, mainly due to $1.15 billion in goodwill and intangible asset impairments.

• 2025 guidance targets 1%-3% core growth, ~14% adjusted EBITDA margin, and EPS of $0.95-$1.05.

Financial highlights

• Q4 2024 sales were $653 million, with core sales up 2% year-over-year after adjusting for currency.

• Adjusted gross margin in Q4 was 57.2%, up nearly 500 basis points year-over-year.

• Adjusted EBITDA margin for Q4 was 13.9%, down from 15.6% in Q4 2023.

• Adjusted EPS for Q4 was $0.24, down from $0.29 in Q4 2023.

• Free cash flow for Q4 was $123.9 million, up from $99.9 million in Q4 2023.

Outlook and guidance

• 2025 guidance: 1%-3% core growth, ~14% adjusted EBITDA margin, and adjusted EPS of $0.95-$1.05.

• Guidance assumes a soft but stable dental market, flat FX rates, and no significant tariff impacts.

• Restructuring expected to generate ~$20 million in annualized savings, mostly benefiting 2025.

• Share repurchase authorization of $250 million through year-end 2026.

• Anticipates slower growth in H1 2025, with improvement in H2 as China orthodontics stabilizes and Spark deferral turns into a tailwind.